The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.

NCT01897870 | Completed

• 1 other identifier: ZGA-1
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

the purpose of this study is to determine the the effect of a home-based medication management program on drug-related problems post-discharge.

Conditions

Adverse Drug Event; Readmission; Patient Compliance

Keywords

continuity of care; medicines management; home visit; drug-related problems

Outcome Measures

Primary Outcomes (1)

• Identifying and solving adverse drug events (ADEs) and other drug-related problems (DRPs) post-discharge

  The total number of assessed and solved ADEs post-discharge will be measured. Assessing and solving ADEs takes place during the pharmacist home visit. Using START-STOPP criteria on patients medication records, ADEs will also be compared between the intervention and usual care group.

  within 7 days post-discharge

Secondary Outcomes (7)

• Improvement of adherence to medication at hospital discharge

  up to 6 months after discharge

• Patient assessment of medication knowledge at time of home visit

  within 7 days after discharge

• Types of interventions made at the pharmacist home visit

  within 7 days after discharge

• Patient satisfaction with the pharmacist home visit

  Immediately after receiving the home visit

• Assessment of patient reported health rating

  at 14 days after discharge

Study Arms (1)

HomeCoMe-program group

EXPERIMENTAL

the arm receiving the pharmacist home visit

Behavioral: HomeCoMe-program

Interventions

HomeCoMe-program BEHAVIORAL

A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.

HomeCoMe-program group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• patient uses more than three prescribed systemic drugs intended for chronic use at admission and discharge
• patient has an expected length of stay of 48 hours or longer

You may not qualify if:

• Patients admitted for scheduled chemotherapy
• Patients admitted for radiation therapy
• Patients admitted for transplantation
• Patients transferred from another hospital
• Patients transferred from another non-eligible ward within the same hospital
• No informed consent signed
• A live expectancy less than 6 months
• Inability to be counselled (e.g. cognitive dysfunction, language constraints who cannot be solved with an interpreter)
• Discharge to a nursing home (presuming dependence on medication administration)
• If patients' community pharmacy is not participating in this study

Sponsors & Collaborators

• H.T. Ensing, PharmD, MSc: lead
• Zorggroep Almere: collaborator
• Flevoziekenhuis: collaborator

Study Sites (1)

Zorgapotheken Flevoland

Almere Stad, Flevoland, 1315RA, Netherlands

Location

Related Publications (3)

• Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, Kachalia A, Horng M, Roy CL, McKean SC, Bates DW. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006 Mar 13;166(5):565-71. doi: 10.1001/archinte.166.5.565.

  PMID: 16534045 BACKGROUND

• Al-Rashed SA, Wright DJ, Roebuck N, Sunter W, Chrystyn H. The value of inpatient pharmaceutical counselling to elderly patients prior to discharge. Br J Clin Pharmacol. 2002 Dec;54(6):657-64. doi: 10.1046/j.1365-2125.2002.01707.x.

  PMID: 12492615 BACKGROUND

• Kwint HF, Faber A, Gussekloo J, Bouvy ML. The contribution of patient interviews to the identification of drug-related problems in home medication review. J Clin Pharm Ther. 2012 Dec;37(6):674-80. doi: 10.1111/j.1365-2710.2012.01370.x. Epub 2012 Aug 3.

  PMID: 22861493 BACKGROUND

MeSH Terms

Conditions

Drug-Related Side Effects and Adverse Reactions; Patient Compliance

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders; Patient Acceptance of Health Care; Treatment Adherence and Compliance; Health Behavior; Behavior

Study Officials

• Marcel L Bouvy, Prof, PharmD, PhD

  UIPS

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PharmD, MSc

Study Record Dates

• First Submitted: July 2, 2013
• First Posted: July 12, 2013
• Study Start: November 1, 2013
• Primary Completion: February 1, 2016
• Study Completion: February 1, 2016
• Last Updated: February 23, 2016

Record last verified: 2016-02

Locations

NL (1)